The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published 7 October 2002. doi:10.1084/jem.20020178
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 249K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feng, Y.
Right arrow Articles by Hadley, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feng, Y.
Right arrow Articles by Hadley, G. A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
Medline Plus Health Information
*Islet Cell Transplantation
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2002/10/877/ $5.00
The Journal of Experimental Medicine, Volume 196, Number 7, October 7, 2002 877-886

CD103 Expression Is Required for Destruction of Pancreatic Islet Allografts by CD8+ T Cells

Ye Feng1, Donghua Wang1, Rongwen Yuan1, Christina M. Parker3, Donna L. Farber1,2 and Gregg A. Hadley1,2

1 Division of Transplantation, Department of Surgery, The University of Maryland Medical Center
2 Department of Microbiology & Immunology, The University of Maryland at Baltimore, Baltimore, MD 21201
3 Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115

Address correspondence to G.A. Hadley, University of Maryland Medical School, Rm. 400 MSTF, 10 South Pine St., Baltimore, MD 21201. Phone: 410-706-0311; Fax: 410-706-0225; E-mail: ghadley{at}smail.umaryland.edu

The mechanisms by which CD8 effector populations interact with epithelial layers is a poorly defined aspect of adaptive immunity. Recognition that CD8 effectors have the capacity to express CD103, an integrin directed to the epithelial cell-specific ligand E-cadherin, potentially provides insight into such interactions. To assess the role of CD103 in promoting CD8-mediated destruction of epithelial layers, we herein examined the capacity of mice with targeted disruption of CD103 to reject pancreatic islet allografts. Wild-type hosts uniformly rejected islet allografts, concomitant with the appearance of CD8+CD103+ effectors at the graft site. In contrast, the majority of islet allografts transplanted into CD103-/- hosts survived indefinitely. Transfer of wild-type CD8 cells into CD103-/- hosts elicited prompt rejection of long-surviving islet allografts, whereas CD103-/- CD8 cells were completely ineffectual, demonstrating that the defect resides at the level of the CD8 cell. CD8 cells in CD103-/- hosts exhibited normal effector responses to donor alloantigens in vitro and trafficked normally to the graft site, but strikingly failed to infiltrate the islet allograft itself. These data establish a causal relationship between CD8+CD103+ effectors and destruction of graft epithelial elements and suggest that CD103 critically functions to promote intragraft migration of CD8 effectors into epithelial compartments.

Key Words: integrins • cytolytic T lymphocytes • epithelial cells • transplantation • graft infiltrating lymphocytes


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS